Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment

NCT02504229 is registered in ClinicalTrials.gov with Beijing Biohealthcare Biotechnology Co.,Ltd as lead sponsor.

NCT NCT02504229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02504229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
Lead sponsor
Beijing Biohealthcare Biotechnology Co.,Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
Not reported
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer